<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Overview of peripheral nerve and muscle disorders causing hypotonia in the newborn</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Overview of peripheral nerve and muscle disorders causing hypotonia in the newborn</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Overview of peripheral nerve and muscle disorders causing hypotonia in the newborn</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Olaf A Bodamer, MD, PhD, FAAP, FACMG</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard Martin, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard P Goddeau, Jr, DO, FAHA</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 08, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Newborns with neuromuscular disorders often present with hypotonia and weakness. These disorders are caused by a variety of systemic conditions and neurologic disorders that affect the central nervous system (brain or spinal cord), peripheral nervous system, or skeletal muscle [<a href="#rid1">1</a>]. Disorders that affect the last two sites are reviewed briefly here  (<a class="graphic graphic_table graphicRef66572" href="/d/graphic/66572.html" rel="external">table 1</a>).</p><p>Central nervous system disorders caused by upper motor neuron lesions that involve the descending motor tracts within the brain and spinal cord and other systemic conditions that cause weakness in infants (eg, cerebral palsy, Prader-Willi syndrome, Angelman syndrome, and multiple minor congenital anomaly syndromes) are presented elsewhere. (See  <a class="medical medical_review" href="/d/html/6167.html" rel="external">"Cerebral palsy: Classification and clinical features"</a> and  <a class="medical medical_review" href="/d/html/5875.html" rel="external">"Prader-Willi syndrome: Clinical features and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/452.html" rel="external">"Congenital cytogenetic abnormalities"</a>.)</p><p>The assessment of weakness and hypotonia in infants is discussed separately. (See  <a class="medical medical_review" href="/d/html/6148.html" rel="external">"Approach to the infant with hypotonia and weakness"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">ANTERIOR HORN CELL DISORDERS</span><span class="headingEndMark"> — </span>Many conditions are caused by degeneration of the anterior horn cells of the spinal cord. They include spinal muscular atrophy, traumatic myelopathy, hypoxic-ischemic myelopathy, and neurogenic arthrogryposis. </p><p class="headingAnchor" id="H3"><span class="h2">Spinal muscular atrophy</span><span class="headingEndMark"> — </span>The most common and severe type that presents in newborns is spinal muscular atrophy (SMA) type 1, also known as Werdnig-Hoffmann disease. This condition should be suspected in infants with diffuse symmetric proximal muscle weakness that is greater in the lower than upper limbs and absent or markedly decreased deep tendon reflexes. SMA types 2 and 3 have later onset and are less severe. (See  <a class="medical medical_review" href="/d/html/6146.html" rel="external">"Spinal muscular atrophy"</a>.)</p><p class="headingAnchor" id="H4"><span class="h2">Traumatic myelopathy</span><span class="headingEndMark"> — </span>Myelopathy caused by trauma to the high cervical spinal cord is a rare cause of hypotonia in infants. This condition results in a flaccid paralysis, which may be asymmetric, and absent reflexes. Physical examination may reveal evidence of trauma, such as bruising or fractures. If no accompanying brain injury is present, the infant will be alert with no cranial nerve abnormalities. A pin prick on the face will elicit a facial grimace but no response below the neck. A useful sign is withdrawal to a noxious stimulus of a limb with no spontaneous activity. Bladder distension, priapism, and absence of sweating below the level of the spinal lesion typically will appear as the myelopathy evolves over several days.</p><p class="headingAnchor" id="H5"><span class="h2">Hypoxic-ischemic myelopathy</span><span class="headingEndMark"> — </span>Severe hypoxic-ischemic injury occasionally can result in hypotonia or flaccid paralysis with diminished or absent reflexes. Affected infants typically have encephalopathy and may have seizures or other signs of end-organ damage. (See  <a class="medical medical_review" href="/d/html/6216.html" rel="external">"Clinical features, diagnosis, and treatment of neonatal encephalopathy"</a>.)</p><p class="headingAnchor" id="H6"><span class="h2">Arthrogryposis multiplex congenita</span><span class="headingEndMark"> — </span>Arthrogryposis (joint contractures) multiplex congenita is a heterogeneous group of disorders characterized by contractures of multiple joints and degeneration of motor neurons. Most cases are neurogenic; the remainder result from primary muscle disease. (See  <a class="medical medical_review" href="/d/html/6146.html" rel="external">"Spinal muscular atrophy", section on 'Arthrogryposis multiplex congenita'</a>.)</p><p class="headingAnchor" id="H7"><span class="h1">CONGENITAL NEUROPATHIES</span><span class="headingEndMark"> — </span>Congenital motor or sensory neuropathies can cause hypotonia and weakness that present during the neonatal period or early infancy. The most important of these conditions are the congenital motor sensory neuropathies and the hereditary sensory and autonomic neuropathies.</p><p class="headingAnchor" id="H8"><span class="h2">Congenital motor sensory neuropathies</span><span class="headingEndMark"> — </span>Congenital (hereditary) motor and sensory neuropathies comprise a heterogeneous group of disorders that affect the peripheral nervous system. These disorders represent a spectrum of diseases caused by mutations in one of several myelin genes that result in defects in myelin structure, maintenance, or formation. Charcot-Marie-Tooth disease is the most common of these conditions. (See  <a class="medical medical_review" href="/d/html/6220.html" rel="external">"Charcot-Marie-Tooth disease: Genetics, clinical features, and diagnosis"</a>.)</p><p class="headingAnchor" id="H9"><span class="h2">Hereditary sensory and autonomic neuropathies</span><span class="headingEndMark"> — </span>Hereditary sensory and autonomic neuropathies are a group of rare disorders that selectively affect peripheral sensory and autonomic neurons  (<a class="graphic graphic_table graphicRef59426" href="/d/graphic/59426.html" rel="external">table 2</a>). They present in infancy and result in a variable extent of autonomic dysfunction or insensitivity to pain and temperature. The most common hereditary sensory and autonomic neuropathy is familial dysautonomia (Riley-Day syndrome). (See  <a class="medical medical_review" href="/d/html/6227.html" rel="external">"Hereditary sensory and autonomic neuropathies"</a>.)</p><p class="headingAnchor" id="H10"><span class="h1">NEUROMUSCULAR JUNCTION DISORDERS</span><span class="headingEndMark"> — </span>Disorders of the neuromuscular junction are characterized by abnormal neuromuscular transmission, leading to muscle fatigability and weakness. These rare conditions include transient acquired neonatal myasthenia, congenital myasthenia, toxicity caused by magnesium or aminoglycosides, and infant botulism. Although most of these disorders are transient, congenital forms sometimes may be permanent. (See  <a class="medical medical_review" href="/d/html/6153.html" rel="external">"Neuromuscular junction disorders in newborns and infants"</a>.)</p><p class="headingAnchor" id="H11"><span class="h1">CONGENITAL MYOPATHIES</span><span class="headingEndMark"> — </span>Congenital myopathies are primary muscle disorders that are present from birth, although their expression may be delayed until later in infancy or childhood. They present with hypotonia and weakness that is greater proximally than distally. The most common diseases are nemaline myopathy, central core disease, myotubular myopathy, congenital fiber type disproportion, and multicore myopathy. (See  <a class="medical medical_review" href="/d/html/6150.html" rel="external">"Congenital myopathies"</a>.)</p><p class="headingAnchor" id="H12"><span class="h1">MUSCULAR DYSTROPHIES</span><span class="headingEndMark"> — </span>The muscular dystrophies are an inherited group of progressive myopathic disorders resulting from defects in numerous genes required for normal muscle function. Some present in the newborn period  (<a class="graphic graphic_table graphicRef66572" href="/d/graphic/66572.html" rel="external">table 1</a>).</p><p class="headingAnchor" id="H13"><span class="h2">Dystrophinopathies</span><span class="headingEndMark"> — </span>The Duchenne and Becker muscular dystrophies are caused by mutations of the dystrophin gene and, therefore, are named dystrophinopathies. Although histologic and laboratory evidence of a myopathy may be observed from birth among male children with Duchenne muscular dystrophy, the clinical onset of weakness usually occurs between two and three years of age, or later. The age of onset of symptoms usually is later and the degree of clinical involvement milder in Becker than Duchenne muscular dystrophy. (See  <a class="medical medical_review" href="/d/html/6149.html" rel="external">"Duchenne and Becker muscular dystrophy: Clinical features and diagnosis"</a>.)</p><p class="headingAnchor" id="H14"><span class="h2">Congenital muscular dystrophies</span><span class="headingEndMark"> — </span>Congenital muscular dystrophies include a number of conditions in which infants are hypotonic and weak at birth and in which muscle biopsies show changes consistent with muscular dystrophy. Arthrogryposis (joint contractures) commonly is observed in the newborn period. (See  <a class="medical medical_review" href="/d/html/6180.html" rel="external">"Oculopharyngeal, distal, and congenital muscular dystrophies", section on 'Congenital muscular dystrophies'</a>.)</p><p>These disorders are classified according to the association with brain malformations and the presence or absence of merosin (a component of the dystrophin-associated protein complex) deficiency. Types associated with brain malformations include Fukuyama type, Walker-Warburg syndrome, and muscle-eye-brain disease. Walker-Warburg syndrome and muscle-eye-brain disease may be due to congenital defects in post-translational protein glycosylation, although genetic heterogeneity has been reported.</p><p class="headingAnchor" id="H15"><span class="h2">Facioscapulohumeral muscular dystrophy</span><span class="headingEndMark"> — </span>Onset of the classical form of this disorder usually is in the second or third decade, and progression typically is slow. However, the infantile form has an earlier onset (usually within the first few years of life) and is rapidly progressive. (See  <a class="medical medical_review" href="/d/html/87096.html" rel="external">"Facioscapulohumeral muscular dystrophy", section on 'Infantile form'</a>.)</p><p class="headingAnchor" id="H16"><span class="h2">Congenital myotonic dystrophy</span><span class="headingEndMark"> — </span>The classic form of myotonic dystrophy has its onset in adolescence or adulthood. The congenital form of the disease occurs in infants born to mothers with myotonic dystrophy. Patients may present with profound hypotonia at birth occurring in association with facial diplegia, feeding, respiratory difficulties, and skeletal deformities such as clubfeet. (See  <a class="medical medical_review" href="/d/html/5147.html" rel="external">"Myotonic dystrophy: Etiology, clinical features, and diagnosis", section on 'Congenital DM1'</a>.)</p><p class="headingAnchor" id="H17"><span class="h1">INBORN ERRORS OF METABOLISM</span><span class="headingEndMark"> — </span>Certain inborn errors of metabolism can present with progressive muscular hypotonia and weakness and/or acute muscle dysfunction with acute muscle breakdown (rhabdomyolysis) or myoglobinuria. These conditions include disorders of glycogen, glycosylation, lipid, peroxisomal, creatine, and mitochondrial metabolism. (See  <a class="medical medical_review" href="/d/html/2930.html" rel="external">"Inborn errors of metabolism: Classification"</a> and  <a class="medical medical_review" href="/d/html/2936.html" rel="external">"Inborn errors of metabolism: Epidemiology, pathogenesis, and clinical features"</a> and  <a class="medical medical_review" href="/d/html/2912.html" rel="external">"Metabolic emergencies in suspected inborn errors of metabolism: Presentation, evaluation, and management"</a>.)</p><p class="headingAnchor" id="H18"><span class="h2">Disorders of glycogen metabolism</span><span class="headingEndMark"> — </span>Among the disorders of glycogen metabolism, only acid maltase deficiency (Pompe disease) typically affects newborns. This condition results in accumulation of glycogen within the lysosomes of tissues, including anterior horn cells of the spinal cord, skeletal muscles, brain, heart, and liver. Affected infants usually develop hypotonia and weakness in the first few weeks after birth, as well as significant cardiomegaly, moderate hepatomegaly, and macroglossia. Early diagnosis of Pompe disease is essential, as specific enzyme replacement therapy is available and appears to benefit affected infants. (See  <a class="medical medical_review" href="/d/html/2905.html" rel="external">"Lysosomal acid alpha-glucosidase deficiency (Pompe disease, glycogen storage disease II, acid maltase deficiency)"</a>.)</p><p>Other abnormalities of glycogen metabolism, such as phosphorylase b kinase deficiency, phosphoglycerate kinase deficiency, and branching enzyme deficiency, typically present later in childhood but can present with hypotonia in infancy. (See  <a class="medical medical_review" href="/d/html/2941.html" rel="external">"Overview of inherited disorders of glucose and glycogen metabolism"</a>.)</p><p class="headingAnchor" id="H19"><span class="h2">Primary carnitine deficiency</span><span class="headingEndMark"> — </span>Primary systemic carnitine deficiency is a disorder of fatty acid oxidation caused by a deficiency of the organic cation/carnitine transporter in the plasma membrane, resulting in defective transport of carnitine from plasma into the cells of affected tissues. This condition typically presents in late infancy or early childhood but can present in the newborn period with weakness, hypotonia, and cardiomyopathy. (See  <a class="medical medical_review" href="/d/html/115918.html" rel="external">"Specific fatty acid oxidation disorders", section on 'Carnitine transporter deficiency'</a>.)</p><p class="headingAnchor" id="H20"><span class="h2">Peroxisomal disorders</span><span class="headingEndMark"> — </span>Peroxisomal disorders can present during the neonatal period with profound hypotonia and weakness. Signs include central nervous system dysfunction, facial dysmorphism (as in Zellweger syndrome), hepatomegaly, cataracts, retinopathy, calcific stippling of epiphyses, and rhizomelia. (See  <a class="medical medical_review" href="/d/html/6147.html" rel="external">"Peroxisomal disorders"</a>.)</p><p class="headingAnchor" id="H21"><span class="h2">Disorders of creatine metabolism</span><span class="headingEndMark"> — </span>Disorders of creatine metabolism encompass three distinct inborn errors of metabolism [<a href="#rid2">2,3</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Guanidinoacetate methyltransferase (GAMT) deficiency [<a href="#rid4">4</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Arginine-glycine amidinotransferase (AGAT) deficiency</p><p class="bulletIndent1"><span class="glyph">●</span>Creatine transporter (CRTR) deficiency</p><p></p><p>Clinical features include muscular hypotonia, epilepsy, extrapyramidal symptoms, and developmental delay. Creatine supplementation and dietary intervention may benefit patients with GAMT and AGAT deficiencies [<a href="#rid2">2,4</a>].</p><p class="headingAnchor" id="H22"><span class="h2">Mitochondrial myopathies</span><span class="headingEndMark"> — </span>Mitochondrial myopathies consist of primary abnormalities of mitochondrial structure and function with an associated involvement of muscle. They are caused by defects of substrate transport, substrate utilization (including the citric acid cycle), and the respiratory chain (oxidative phosphorylation coupling). Respiratory chain abnormalities are most likely to lead to prominent muscle disease in the newborn. (See  <a class="medical medical_review" href="/d/html/6197.html" rel="external">"Metabolic myopathies caused by disorders of lipid and purine metabolism"</a> and  <a class="medical medical_review" href="/d/html/5151.html" rel="external">"Mitochondrial myopathies: Clinical features and diagnosis"</a>.)</p><p>Mitochondrial myopathy should be suspected in an infant with weakness and lactic acidosis, especially if multisystem involvement is present.</p><p class="headingAnchor" id="H23"><span class="h3">Cytochrome c oxidase deficiency</span><span class="headingEndMark"> — </span>Cytochrome c oxidase (COX, complex IV) deficiency is the most common respiratory chain disorder causing myopathy in newborns [<a href="#rid5">5,6</a>]. The enzyme deficiency results in impairment of energy production. Affected patients present within the first days or weeks with profound generalized weakness, hypotonia, hyporeflexia, poor feeding, respiratory difficulty, and lactic acidosis (caused by decreased utilization of pyruvate, which is then converted to lactate). They also may have macroglossia, hepatomegaly, and cardiomyopathy. The disease is fatal within a few months. Some of these individuals have renal defects (de Toni-Debré-Fanconi syndrome) with impaired proximal tubular function that may lead to glucosuria, tubular proteinuria (including generalized amino aciduria), renal tubular acidosis, hypokalemia, and hypouricemia. </p><p>Cytochrome c oxidase deficiency also can result in a reversible myopathy caused by a maternally inherited mutations (m.14674T&gt;C or m.14674T&gt;G) involving the mitochondrial transfer RNA for glutamic acid [<a href="#rid7">7-11</a>]. The presentation of this condition is similar to that of the severe neonatal form. The condition is life-threatening in the first months after birth. Thereafter, infants improve biochemically and clinically over one to two years.</p><p>Other presentations of cytochrome c oxidase deficiency have a more prominent encephalopathic component (eg, Leigh syndrome) [<a href="#rid12">12,13</a>]. (See  <a class="medical medical_review" href="/d/html/6226.html" rel="external">"Neuropathies associated with hereditary disorders", section on 'Leigh syndrome'</a>.)</p><p>Cytochrome c oxidase deficiency is associated with pathologic mutations in more than 30 genes involving both mitochondrial and nuclear DNA [<a href="#rid14">14</a>]. </p><p>The serum creatine kinase concentration may be slightly elevated in this disorder, although the electromyography usually is normal. Muscle biopsy shows nonspecific myopathic changes and ragged red fibers on Gomori trichrome staining, which is strong evidence for mitochondrial disease. Deficiency of cytochrome c oxidase is apparent on histochemical staining. Electron microscopy reveals accumulation of lipid and glycogen and an increased number of large abnormal appearing mitochondria in the muscle fibers. The severe and benign conditions can be differentiated on muscle biopsy.</p><p class="headingAnchor" id="H3375809"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Anterior horn cell disorders </strong>– Degeneration of the anterior horn cells of the spinal cord can occur in spinal muscular atrophy, traumatic myelopathy, hypoxic-ischemic myelopathy, and neurogenic arthrogryposis. (See <a class="local">'Anterior horn cell disorders'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Congenital neuropathies </strong>– Congenital neuropathies can cause hypotonia and weakness that present during the neonatal period or early infancy. The most important of these conditions are the congenital motor sensory neuropathies and the hereditary sensory and autonomic neuropathies. (See <a class="local">'Congenital neuropathies'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neuromuscular junction disorders </strong>– Disorders of the neuromuscular junction are characterized by abnormal neuromuscular transmission, leading to muscle fatigability and weakness. These rare conditions include transient acquired neonatal myasthenia, congenital myasthenia, toxicity caused by magnesium or aminoglycosides, and infant botulism. (See  <a class="medical medical_review" href="/d/html/6153.html" rel="external">"Neuromuscular junction disorders in newborns and infants"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Congenital myopathies </strong>– Congenital myopathies are primary muscle disorders that are present from birth, although their expression may be delayed until later in infancy or childhood. They present with hypotonia and weakness that is greater proximally than distally. The most common diseases are nemaline myopathy, central core disease, myotubular myopathy, congenital fiber type disproportion, and multicore myopathy. (See  <a class="medical medical_review" href="/d/html/6150.html" rel="external">"Congenital myopathies"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Muscular dystrophies </strong>– The muscular dystrophies are an inherited group of progressive myopathic disorders resulting from defects in numerous genes required for normal muscle function. Some present in the newborn period  (<a class="graphic graphic_table graphicRef66572" href="/d/graphic/66572.html" rel="external">table 1</a>). (See <a class="local">'Muscular dystrophies'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Inborn errors of metabolism </strong>– Certain inborn errors of metabolism can present with progressive muscular hypotonia and weakness and/or acute muscle dysfunction with muscle breakdown or myoglobinuria. These conditions include disorders of glycogen, lipid, peroxisomal, creatine, and mitochondrial metabolism. (See <a class="local">'Inborn errors of metabolism'</a> above.)</p><p></p><p class="headingAnchor" id="H1472479336"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Geoffrey Miller, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Sparks SE. Neonatal hypotonia. Clin Perinatol 2015; 42:363.</a></li><li><a class="nounderline abstract_t">Stromberger C, Bodamer OA, Stöckler-Ipsiroglu S. Clinical characteristics and diagnostic clues in inborn errors of creatine metabolism. J Inherit Metab Dis 2003; 26:299.</a></li><li><a class="nounderline abstract_t">Joncquel-Chevalier Curt M, Voicu PM, Fontaine M, et al. Creatine biosynthesis and transport in health and disease. Biochimie 2015; 119:146.</a></li><li><a class="nounderline abstract_t">Mercimek-Mahmutoglu S, Stoeckler-Ipsiroglu S, Adami A, et al. GAMT deficiency: features, treatment, and outcome in an inborn error of creatine synthesis. Neurology 2006; 67:480.</a></li><li><a class="nounderline abstract_t">Tritschler HJ, Bonilla E, Lombes A, et al. Differential diagnosis of fatal and benign cytochrome c oxidase-deficient myopathies of infancy: an immunohistochemical approach. Neurology 1991; 41:300.</a></li><li><a class="nounderline abstract_t">DiMauro S, Lombes A, Nakase H, et al. Cytochrome c oxidase deficiency. Pediatr Res 1990; 28:536.</a></li><li><a class="nounderline abstract_t">Salo MK, Rapola J, Somer H, et al. Reversible mitochondrial myopathy with cytochrome c oxidase deficiency. Arch Dis Child 1992; 67:1033.</a></li><li><a class="nounderline abstract_t">Wada H, Woo M, Nishio H, et al. Vascular involvement in benign infantile mitochondrial myopathy caused by reversible cytochrome c oxidase deficiency. Brain Dev 1996; 18:263.</a></li><li><a class="nounderline abstract_t">Horvath R, Kemp JP, Tuppen HA, et al. Molecular basis of infantile reversible cytochrome c oxidase deficiency myopathy. Brain 2009; 132:3165.</a></li><li><a class="nounderline abstract_t">Mimaki M, Hatakeyama H, Komaki H, et al. Reversible infantile respiratory chain deficiency: a clinical and molecular study. Ann Neurol 2010; 68:845.</a></li><li><a class="nounderline abstract_t">Guerrero JC, Pedro H, Parisotto S, et al. A Case of Reversible Infantile Respiratory Chain Deficiency Presenting With Hypotonia, Hyperammonemia, and Failure to Thrive. Pediatr Dev Pathol 2019; 22:590.</a></li><li><a class="nounderline abstract_t">Shoubridge EA. Cytochrome c oxidase deficiency. Am J Med Genet 2001; 106:46.</a></li><li><a class="nounderline abstract_t">Robinson BH. Human cytochrome oxidase deficiency. Pediatr Res 2000; 48:581.</a></li><li><a class="nounderline abstract_t">Rak M, Bénit P, Chrétien D, et al. Mitochondrial cytochrome c oxidase deficiency. Clin Sci (Lond) 2016; 130:393.</a></li></ol></div><div id="topicVersionRevision">Topic 6151 Version 23.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26042909" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Neonatal hypotonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12889668" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Clinical characteristics and diagnostic clues in inborn errors of creatine metabolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26542286" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Creatine biosynthesis and transport in health and disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16855203" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : GAMT deficiency: features, treatment, and outcome in an inborn error of creatine synthesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1846953" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Differential diagnosis of fatal and benign cytochrome c oxidase-deficient myopathies of infancy: an immunohistochemical approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2175026" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Cytochrome c oxidase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1325759" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Reversible mitochondrial myopathy with cytochrome c oxidase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8879644" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Vascular involvement in benign infantile mitochondrial myopathy caused by reversible cytochrome c oxidase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19720722" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Molecular basis of infantile reversible cytochrome c oxidase deficiency myopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21194154" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Reversible infantile respiratory chain deficiency: a clinical and molecular study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31333056" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : A Case of Reversible Infantile Respiratory Chain Deficiency Presenting With Hypotonia, Hyperammonemia, and Failure to Thrive.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11579424" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Cytochrome c oxidase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11044474" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Human cytochrome oxidase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26846578" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Mitochondrial cytochrome c oxidase deficiency.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
